Glp-1 analog fusion protein formulations
The invention provides a stable solution formulation comprising a GLP-1-Fc fusion at a pH between about pH 6 and about pH 8.5. analogs fused to specific IgG4-Fc derivatives. These formulations provide unexpected and considerably greater chemical stability than when compared to GLP-1-Fc fusions at a...
Saved in:
Main Author | |
---|---|
Format | Patent |
Language | English |
Published |
26.09.2007
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The invention provides a stable solution formulation comprising a GLP-1-Fc fusion at a pH between about pH 6 and about pH 8.5. analogs fused to specific IgG4-Fc derivatives. These formulations provide unexpected and considerably greater chemical stability than when compared to GLP-1-Fc fusions at a pH outside the described ranges. The formulations comprising a GLP-1-Fc fusion are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake. |
---|---|
AbstractList | The invention provides a stable solution formulation comprising a GLP-1-Fc fusion at a pH between about pH 6 and about pH 8.5. analogs fused to specific IgG4-Fc derivatives. These formulations provide unexpected and considerably greater chemical stability than when compared to GLP-1-Fc fusions at a pH outside the described ranges. The formulations comprising a GLP-1-Fc fusion are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake. |
Author | GLAESNER WOLFGANG,MILLICAN ROHN LEE JUNIOR |
Author_xml | – fullname: GLAESNER WOLFGANG,MILLICAN ROHN LEE JUNIOR |
BookMark | eNrjYmDJy89L5WTQcM8p0DVUSMxLzMlPV0grLc7Mz1MoKMovSc3MU0jLL8otzUksAYoV8zCwpiXmFKfyQmluBkU31xBnD93Ugvz41OKCxOTUvNSSeGc_QwNDAxMTQzMjR2Ni1AAAoAEp3g |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences |
ExternalDocumentID | CN101044162A |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_CN101044162A3 |
IEDL.DBID | EVB |
IngestDate | Fri Jul 19 14:00:35 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_CN101044162A3 |
Notes | Application Number: CN200580035597 |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20070926&DB=EPODOC&CC=CN&NR=101044162A |
ParticipantIDs | epo_espacenet_CN101044162A |
PublicationCentury | 2000 |
PublicationDate | 20070926 |
PublicationDateYYYYMMDD | 2007-09-26 |
PublicationDate_xml | – month: 09 year: 2007 text: 20070926 day: 26 |
PublicationDecade | 2000 |
PublicationYear | 2007 |
RelatedCompanies | LILLY CO. ELI |
RelatedCompanies_xml | – name: LILLY CO. ELI |
Score | 2.6889274 |
Snippet | The invention provides a stable solution formulation comprising a GLP-1-Fc fusion at a pH between about pH 6 and about pH 8.5. analogs fused to specific... |
SourceID | epo |
SourceType | Open Access Repository |
SubjectTerms | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE |
Title | Glp-1 analog fusion protein formulations |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20070926&DB=EPODOC&locale=&CC=CN&NR=101044162A |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NS8MwFH_MKepNp6LzgwpSvATbrGvXQxGXtg5h3ZApu40mpLAhtdgO_31fYuu86C0k4eUD3mfyfg_gRtBMZpIL4vgCHZSe45NUOAPCbcqFhUKZ65qR48QdvThP8_68BasmF0bjhH5qcETkKIH8Xml5XWyCWKH-W1ne8SV2vd_HsyA0G-_Ys3zqmuEwiKaTcMJMxgKWmMkz2rrod6DxQR-2YFuZ0QpnP3odqqyU4rdKiQ9gZ4rU8uoQWjLvwB5rKq91YHdcP3hjs-a98ghuH98KYhtprsItRrZWYS5Dwywsc0OZnnUhrvIYruNoxkYEl1z8nG_Bks3ueifQRr9fnoJBLZ66vi2Q46iqC516vsdx3iBLsz5P5Rl0_6bT_W_wHPa_Q5Q-oe4FtKuPtbxE3VrxK30pXyKBfX0 |
link.rule.ids | 230,309,786,891,25594,76906 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NS8MwFH_MKc6bTmXOrwpSvBTbrGvXQxGXrk5duyFVditNaGEitdgO_31f4uq86C0k4eUD3mfyfg_gkpMszVLGNdPh6KD0TEdLuDnQmEEY11EoM1kzMgit8bP5MO_PG_Ba58JInNBPCY6IHMWR3yspr4t1EMuTfyvLa7bArvcbP3I9tfaObd0hluoN3dFs6k2pSqlLQzV8QlsX_Q40PsjtBmzaAp1XmE4vQ5GVUvxWKf4ubM2QWl7tQSPN29CideW1NmwHqwdvbK54r9yHq7u3QjOUJBfhFiVbijCXImEWFrkiTM9VIa7yAC78UUTHGi4Z_5wvpuF6d71DaKLfn3ZAITpLLMfgyHFE1IVObMdmOG-QJVmfJekRdP-m0_1v8Bxa4yiYxJP78PEYdr7DlY5GrBNoVh_L9BT1bMXO5AV9ASiTgGo |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Glp-1+analog+fusion+protein+formulations&rft.inventor=GLAESNER+WOLFGANG%2CMILLICAN+ROHN+LEE+JUNIOR&rft.date=2007-09-26&rft.externalDBID=A&rft.externalDocID=CN101044162A |